# Contact Doctor Retatrutide | Retatrutide Research Digest

> Contact Doctor Retatrutide with editorial questions or factual corrections about the retatrutide research literature. Not a medical service.

Doctor Retatrutide is an independent editorial digest of the published retatrutide (LY3437943) clinical literature. The contact form below is for editorial inquiries and factual corrections only.

## What We Can Help With

We review and respond to substantive factual corrections — if a citation is broken, a number is wrong, or a study has been updated since publication, we want to know. We also welcome editorial feedback on clarity and completeness.

We cannot help with medical questions, individual health decisions, clinical trial enrollment inquiries, or requests for access to retatrutide. This site does not have clinical staff and does not offer any service related to drug access or prescription.

## Editorial Disclaimer

Doctor Retatrutide is not a clinic, not a pharmacy, and not a medical service. It does not sell, distribute, or recommend any compound. All content is a summary of publicly available peer-reviewed research on retatrutide. Nothing on this site constitutes medical advice, clinical guidance, or a recommendation to seek out retatrutide outside of an authorized clinical trial setting.

Retatrutide is an investigational drug not approved by the FDA for any indication as of mid-2026. It is available only through authorized Lilly-sponsored clinical trials.

## Send a Message

Use the form below to submit an editorial inquiry or factual correction. Please include the page and the specific claim you are writing about.

---

A cinematic index of the Phase 2 and Phase 3 retatrutide trial record — primary sources only, no clinic, no prescription.